Takeda On Continued Lookout For Assets After Recent Deals

Reports Solid Q3 Results

Leading Japanese firm reports solid growth in its fiscal nine months as it hints more may be to come after recent major deals to expand the mid- to late-stage pipeline and highlights progress for some key internal assets.

lookout
Takeda on lookout for pipeline assets • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd.’s recent huge deal for Nimbus Therapeutics, Inc.’s Phase IIb stage oral TYK2 inhibitor and progress for a closely-watched in-house narcolepsy program both featured prominently in the leading Japanese firm’s fiscal third-quarter results briefing, after it announced results seen as another solid performance.

President and CEO Christophe Weber told a 2 February conference call that the results “very clearly keep us on track...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

 

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.

2025’s Biggest Launches – Half-Year Progress Report

 

Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By 

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.